These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23010274)

  • 1. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
    Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.
    Giordanetto F; Wållberg A; Ghosal S; Iliefski T; Cassel J; Yuan ZQ; von Wachenfeldt H; Andersen SM; Inghardt T; Tunek A; Nylander S
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6671-6. PubMed ID: 23010262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
    Kim J; Hong S; Hong S
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6977-81. PubMed ID: 22030027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening.
    Giordanetto F; Kull B; Dellsén A
    Bioorg Med Chem Lett; 2011 Jan; 21(2):829-35. PubMed ID: 21169017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Okada M; Ohta M; Tsukamoto S; Parker P; Workman P; Waterfield M
    Bioorg Med Chem; 2006 Oct; 14(20):6847-58. PubMed ID: 16837202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
    Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
    Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
    Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
    J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.
    Marshall AJ; Lill CL; Chao M; Kolekar SV; Lee WJ; Marshall ES; Baguley BC; Shepherd PR; Denny WA; Flanagan JU; Rewcastle GW
    Bioorg Med Chem; 2015 Jul; 23(13):3796-808. PubMed ID: 25890698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
    Morales GA; Garlich JR; Su J; Peng X; Newblom J; Weber K; Durden DL
    J Med Chem; 2013 Mar; 56(5):1922-39. PubMed ID: 23410005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.
    Knight ZA; Chiang GG; Alaimo PJ; Kenski DM; Ho CB; Coan K; Abraham RT; Shokat KM
    Bioorg Med Chem; 2004 Sep; 12(17):4749-59. PubMed ID: 15358300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.
    Pecchi S; Ni ZJ; Han W; Smith A; Lan J; Burger M; Merritt H; Wiesmann M; Chan J; Kaufman S; Knapp MS; Janssen J; Huh K; Voliva CF
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4652-6. PubMed ID: 23820386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors.
    Kendall JD; Rewcastle GW; Frederick R; Mawson C; Denny WA; Marshall ES; Baguley BC; Chaussade C; Jackson SP; Shepherd PR
    Bioorg Med Chem; 2007 Dec; 15(24):7677-87. PubMed ID: 17869522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
    Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
    J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
    Wang J; Wang X; Chen Y; Chen S; Chen G; Tong L; Meng L; Xie Y; Ding J; Yang C
    Bioorg Med Chem Lett; 2012 Jan; 22(1):339-42. PubMed ID: 22130133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.
    Beeton CA; Chance EM; Foukas LC; Shepherd PR
    Biochem J; 2000 Sep; 350 Pt 2(Pt 2):353-9. PubMed ID: 10947948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.
    Staben ST; Siu M; Goldsmith R; Olivero AG; Do S; Burdick DJ; Heffron TP; Dotson J; Sutherlin DP; Zhu BY; Tsui V; Le H; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Sideris S; Wiesmann C; Wu P
    Bioorg Med Chem Lett; 2011 Jul; 21(13):4054-8. PubMed ID: 21636270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment based discovery of a novel and selective PI3 kinase inhibitor.
    Hughes SJ; Millan DS; Kilty IC; Lewthwaite RA; Mathias JP; O'Reilly MA; Pannifer A; Phelan A; Stühmeier F; Baldock DA; Brown DG
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6586-90. PubMed ID: 21925880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.